Citeline Podcasts

Scrip’s Five Must-Know Things – 14 March 2022 by Citeline

Pink Sheet reporter and editors discuss new accelerated approval legislation, the changing FDA patient-focused drug development initiative, and the importance of access for COVID-19 treatments.

In this edition of Device Week, Medtech Insight’s Reed Miller chats with UK-based reporter Barnaby Pickering about Zimmer Biomet’s recent spin-off of its spinal and dental businesses under the name ZimVie, and Marion Webb explains the emerging field of femtech, which includes innovations to treat often-overlooked needs in women’s health.

Listen to the podcast via the player below:

Medtech Insight articles addressing topics discussed in this episode:

Zimmer Biomet Spin-Off’s Share Price Plummets

https://medtech.pharmaintelligence.informa.com/MT145159/Zimmer-Biomet-Spin-Offs-Share-Price-Plummets

‘Femtech’ Evolving Beyond Periods, Pregnancy And Postpartum: What’s Next In $1.2Tr Women’s Health

https://medtech.pharmaintelligence.informa.com/MT145121/Femtech-Evolving-Beyond-Periods-Pregnancy-And-Postpartum-Whats-Next-In-12Tr-Womens-Health

For MedTech Europe’s Patrick Boisseau, the newly launched Innovative Health Initiative is a real “game changer.” In this interview, he explains how companies should get involved in cross-sectoral medtech/pharma projects that will revolutionize European healthcare innovation.

Scrip’s Five Must-Know Things – 7 March 2022 by Citeline

Device Week, 4 March 2022 - FDA Gets First Feedback On QMSR Draft Reg by Citeline

Exploring The Spinal Cord Stimulation Devices Market by Citeline

Davinderpreet Mangat, Ellie Davenport, and Millie Gray provide a thought leadership piece on PARP inhibitors in various oncology markets.

Supporting links:

Breast cancer - https://service.datamonitorhealthcare.com/disease/oncology/gynecological-cancer/breast-cancer-hr-her2/disease-analysis/article212246.ece

https://service.datamonitorhealthcare.com/disease/oncology/gynecological-cancer/breast-cancer-triple-negative/disease-analysis/article210516.ece

Ovarian cancer - https://service.datamonitorhealthcare.com/disease/oncology/gynecological-cancer/ovarian-cancer/disease-analysis/article215125.ece

Pancreatic cancer - https://service.datamonitorhealthcare.com/disease/oncology/gastrointestinal-cancer/pancreatic-cancer/market-spotlight/article200459.ece

Prostate cancer - https://service.datamonitorhealthcare.com/disease/oncology/urological-cancer/prostate-cancer/disease-analysis/article223558.ece

Other platforms:

Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836

Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz

TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/

Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67

In this episode, HBW Insight talks probiotics with David Pineda Ereño, founder of DPE International Consulting and consultant to the International Probiotics Association. Since 2006, no health claims for probiotics have been allowed by harmonised European Union regulations. Even the term probiotics is considered an unauthorised health claim by the European Commission. However, as David explains, many EU member states, including Italy and Spain, are starting to go their own way, adopting a more liberal approach to this booming wellness market. We discuss what the future of EU probiotics regulation may hold, as well as some of the exciting science that is coming out all the time, pointing to the health benefits of this extremely popular ingredient.

Scrip’s Five Must-Know Things – 28 February 2022 by Citeline